醋酸甲地孕酮对晚期结直肠癌患者化疗效果的影响

Effects of Megestrol Acetate on Chemotherapeutic Efficacy in Patients with Advanced Colorectal Cancer

目的:探讨醋酸甲地孕酮对晚期结直肠癌患者化疗效果的影响。方法:选取2015年1月至2017年12月北京大学首钢医院收治的晚期结直肠癌患者50例作为研究对象,采用随机数字表法分为观察组26例和对照组24例。两组患者均采用XELOX方案(奥沙利铂+卡培他滨)化疗,在此基础上,观察组患者加用醋酸甲地孕酮,口服,1日160 mg。观察两组患者的临床疗效、体质量指数、卡氏评分及不良反应发生情况。结果:观察组患者的总有效率、肿瘤控制率分别为38.5%(10/26)、53.8%(14/26),略高于对照组的29.2%(7/24)、45.8%(11/24),但差异无统计学意义(P>0.05)。治疗后,两组患者体质量指数和卡氏评分均有一定的改善,且观察组患者明显高于对照组,差异均有统计学意义(P<0.05)。观察组患者的纳差/厌食发生率明显低于对照组,差异有统计学意义(P<0.05)。结论:晚期结直肠癌患者在化疗过程中口服醋酸甲地孕酮辅助治疗,不影响临床疗效,但可改善患者的体质量指数和体力状态,且不良反应少。

OBJECTIVE：To probe into the effects of megestrol acetate on chemotherapeutic efficacy in patients with advanced colorectal cancer. METHODS：50 patients with advanced colorectal cancer admitted into Peking University Shougang Hospital from Jan. 2015 to Dec. 2017 were selected and divided into observation group（26 cases）and control group（24 cases） via random number table. Both groups were given XELOX chemotherapy of oxaliplatin combined with xeloda, on that basis, the observation group was given megestrol acetate orally with 160 mg a day. The clinical efficacy, body mass index（BMI）, Karnofsky performance status（KPS） and incidences of adverse drug reactions of two gorups were observed. RESULTS：The total effective rate and tumor control probability of observation group were respectively 38.5%（10/26） and 53.8%（14/26）, which were slightly higher than those of the control group（29.2%, 7/24; 45.8%, 11/24）, with no statistically significant differences（P0.05）. After treatment, the BMI and KPS of both groups had been improved, and those of the observation group were significantly higher than the control group, with statistically significant differences（P0.05）. The incidence of poor appetite/anorexia of observation group was significantly lower than that of the control group,with statistically significant differences（P0.05）. CONCLUSIONS：Oral administration of megestrol acetate for adjuvant therapy in the chemotherapy on patients with advanced colorectal cancer has no effects on clinical efficacy, but can improve the body mass index and physical state of the patient, with fewer adverse drug reactions.